Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumabRenaud Heine, Carin A. Uyl‐de Groot, Frederick W. Thielen et al.|PLoS ONE|2024Cited by 6